RESUMO
Safety, tolerability and antihypertensive efficacy of a cardioselective beta-blocker nebivolol was studied in 30 patients with mild and moderate hypertension and concomitant stage I chronic obstructive bronchitis. Nebivolol (5 mg/day) was given for 1 month; in 5 patients complementary hydrochlorothiazide (12.5 mg/day) was required for sufficient antihypertensive effect. Nebivolol was well tolerated (only 1 patient complained of head ache), did not cause worsening of bronchitis and spirometric parameters, exerted no cardiodepressive action, and did not induce apparent disturbances of metabolism.
Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Benzopiranos/uso terapêutico , Bronquite Crônica/complicações , Etanolaminas/uso terapêutico , Hipertensão/complicações , Hipertensão/tratamento farmacológico , Antagonistas Adrenérgicos beta/efeitos adversos , Adulto , Benzopiranos/efeitos adversos , Etanolaminas/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , NebivololRESUMO
A method for measuring serum ribose by gas liquid chromatography is described, prolonging the sample stability and simplifying its storage. Serum ribose content is decreased in patients with angina of effort (functional class III).